Max Lonneux MD , Ivan Borbath MD , Martine Berlière MD , Carine Kirkove MD , Stanislas Pauwels MD, PhD
{"title":"全身PET FDG在乳腺癌远处复发诊断中的地位","authors":"Max Lonneux MD , Ivan Borbath MD , Martine Berlière MD , Carine Kirkove MD , Stanislas Pauwels MD, PhD","doi":"10.1016/S1095-0397(00)00042-X","DOIUrl":null,"url":null,"abstract":"<div><p><strong>Purpose:</strong> To study the role of positron emission tomography <sup>18</sup>F-fluorodeoxyglucose (PET FDG) imaging in patients with a suspicion of breast cancer recurrence.</p><p><strong>Procedures:</strong> Whole-body PET FDG was performed in 39 women. Thirty-four were included because of asymptomatic tumor marker increase. PET findings were confirmed by oriented imaging or by biopsy. Follow-up data were collected over a period of at least 12 months.</p><p><strong>Results:</strong> PET FDG depicted 37/39 sites in 31/33 patients with recurrence. PET missed one locoregional recurrence and in one patient peritoneal carcinomatosis developed 6 months after a negative PET. False positive PET FDG corresponded to lung infection, degenerative bone disease, and reconstruction artifact. The conventional imaging work-up depicted sites of recurrence in 6/33 patients.</p><p><strong>Conclusion:</strong> Whole-body PET FDG is highly sensitive for the detection of distant breast cancer recurrence. Prospective studies are mandatory to address its potential impact on patient management and survival.</p></div>","PeriodicalId":80267,"journal":{"name":"Clinical positron imaging : official journal of the Institute for Clinical P.E.T","volume":"3 2","pages":"Pages 45-49"},"PeriodicalIF":0.0000,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1095-0397(00)00042-X","citationCount":"94","resultStr":"{\"title\":\"The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer\",\"authors\":\"Max Lonneux MD , Ivan Borbath MD , Martine Berlière MD , Carine Kirkove MD , Stanislas Pauwels MD, PhD\",\"doi\":\"10.1016/S1095-0397(00)00042-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><strong>Purpose:</strong> To study the role of positron emission tomography <sup>18</sup>F-fluorodeoxyglucose (PET FDG) imaging in patients with a suspicion of breast cancer recurrence.</p><p><strong>Procedures:</strong> Whole-body PET FDG was performed in 39 women. Thirty-four were included because of asymptomatic tumor marker increase. PET findings were confirmed by oriented imaging or by biopsy. Follow-up data were collected over a period of at least 12 months.</p><p><strong>Results:</strong> PET FDG depicted 37/39 sites in 31/33 patients with recurrence. PET missed one locoregional recurrence and in one patient peritoneal carcinomatosis developed 6 months after a negative PET. False positive PET FDG corresponded to lung infection, degenerative bone disease, and reconstruction artifact. The conventional imaging work-up depicted sites of recurrence in 6/33 patients.</p><p><strong>Conclusion:</strong> Whole-body PET FDG is highly sensitive for the detection of distant breast cancer recurrence. Prospective studies are mandatory to address its potential impact on patient management and survival.</p></div>\",\"PeriodicalId\":80267,\"journal\":{\"name\":\"Clinical positron imaging : official journal of the Institute for Clinical P.E.T\",\"volume\":\"3 2\",\"pages\":\"Pages 45-49\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1095-0397(00)00042-X\",\"citationCount\":\"94\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical positron imaging : official journal of the Institute for Clinical P.E.T\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S109503970000042X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical positron imaging : official journal of the Institute for Clinical P.E.T","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S109503970000042X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer
Purpose: To study the role of positron emission tomography 18F-fluorodeoxyglucose (PET FDG) imaging in patients with a suspicion of breast cancer recurrence.
Procedures: Whole-body PET FDG was performed in 39 women. Thirty-four were included because of asymptomatic tumor marker increase. PET findings were confirmed by oriented imaging or by biopsy. Follow-up data were collected over a period of at least 12 months.
Results: PET FDG depicted 37/39 sites in 31/33 patients with recurrence. PET missed one locoregional recurrence and in one patient peritoneal carcinomatosis developed 6 months after a negative PET. False positive PET FDG corresponded to lung infection, degenerative bone disease, and reconstruction artifact. The conventional imaging work-up depicted sites of recurrence in 6/33 patients.
Conclusion: Whole-body PET FDG is highly sensitive for the detection of distant breast cancer recurrence. Prospective studies are mandatory to address its potential impact on patient management and survival.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
